HC Wainwright Issues Pessimistic Estimate for VTVT Earnings

vTv Therapeutics Inc. (NASDAQ:VTVT) – Investment analysts at HC Wainwright reduced their Q3 2026 EPS estimates for vTv Therapeutics in a research report issued to clients and investors on Thursday, August 6th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn ($1.01) per share for the quarter, down from their previous forecast of ($0.54). HC Wainwright currently has a “Buy” rating and a $42.00 price objective on the stock. The consensus estimate for vTv Therapeutics’ current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for vTv Therapeutics’ Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($4.60) EPS, FY2028 earnings at ($4.40) EPS, FY2029 earnings at ($3.78) EPS and FY2030 earnings at ($3.61) EPS.

vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08).

A number of other analysts have also recently commented on VTVT. Rodman & Renshaw started coverage on vTv Therapeutics in a research report on Tuesday, June 30th. They set a “buy” rating and a $67.00 price objective for the company. Wall Street Zen lowered shares of vTv Therapeutics from a “buy” rating to a “sell” rating in a report on Saturday. Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th. Zacks Research cut shares of vTv Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Finally, BTIG Research lifted their price target on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Six research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $55.83.

vTv Therapeutics Stock Down 3.6%

Shares of NASDAQ:VTVT opened at $33.04 on Monday. vTv Therapeutics has a 52-week low of $14.00 and a 52-week high of $44.00. The stock’s fifty day simple moving average is $33.40 and its 200-day simple moving average is $34.81. The company has a market capitalization of $130.14 million, a P/E ratio of -31.17 and a beta of 0.29.

Hedge Funds Weigh In On vTv Therapeutics

Several institutional investors have recently added to or reduced their stakes in VTVT. 683 Capital Management LLC purchased a new position in vTv Therapeutics during the fourth quarter worth about $731,000. Goldman Sachs Group Inc. purchased a new stake in vTv Therapeutics in the 4th quarter valued at about $221,000. Finally, Geode Capital Management LLC increased its stake in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after acquiring an additional 12,896 shares during the last quarter. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.